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Facial discoid dermatosis (FDD) is a recently described condition
comprising discrete facial papulo‐squamous lesions. We report three cases
that clinically and histologically resemble FDD and demonstrate its resis-
tance to treatment. Awareness of this new clinical entity will allow early
diagnosis and the ability to make patients aware that there is unlikely to be a
successful treatment. However, our study suggests that although FDD can
persist for many years, it appears to remain stable.
1 | INTRODUCTION
We have seen three cases with multiple persistent
discoid well‐defined psoriasiform lesions on the face that
do not fit a well‐known clinical or histological diagnosis
and do not respond to a myriad of therapies. The entity
facial discoid dermatosis (FDD) has been suggested for
this group of disorders.1 It presents as discrete thin
papulo‐squamous pink‐orange lesions that localise to
the face, sometimes accompanied with scale, that are
highly resistant to treatment, though remain stable for
many years. Awareness of this new clinical entity will
allow early diagnosis of patients who have similar
persistent facial lesions. With increased reporting of this
rare entity, there will be progress in further defining its
characteristics and management strategies.
2 | REPORT
Case 1 A 19‐year‐old male with Fitzpatrick Skin
Type 2 presented with an 18‐month history of an
asymptomatic facial rash. Antecedent treatments
included coal tar, hydrocortisone and allantoin
cream and Clotrimazole 1% cream. On exami-
nation he had discrete orange‐pink slightly scaly
discoid plaques on the cheeks and forehead
(Figure 1a). He was clinically diagnosed with
sebopsoriasis however failed to respond to clo-
betasone 17‐butyrate 0.05%w/w, oxytetracycline
3.0%w/w as calcium oxytetracycline and nystatin
100 000 units per gram cream, clobetasone
butyrate 0.05% ointment, mometasone furoate
0.1% ointment, clobetasol propionate 0.05%
ointment, ketoconazole 2% shampoo, tacrolimus
0.1% ointment, pimecrolimus 1% cream and
tacalcitol ointment. Systemic itraconazole 200mg
once a day for 4 weeks and oxytetracycline
500 mg twice daily for 8 weeks was also trialled
without response. A biopsy showed hyperkera-
tosis, parakeratosis, acanthosis, follicular plug-
ginganda lymphocytic infiltration in the superficial
dermis (Figure 2a). Staining for periodic acid‐
Schiff (PAS) was negative. On the basis that the
rash may represent psoriasis, the patient was
treated with Narrowband UVB phototherapy
(NBUVB) and Acitretin 25 mg once a day for
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8 weeks but the facial plaques persisted. A trial of
hydroxychloroquine 200 mg twice daily for
12 weeks for a presumed clinical diagnosis of
discoid lupus erythematosus (DLE) gave no clin-
ical improvement. This was followed by cryo-
therapy and five sessions of pulsed dye laser
which was also ineffective. His lesions have per-
sisted but have remained stable in number and
extent without progression during a follow up
period of 8 years.
Case 2 A 40‐year‐old female with Fitzpatrick Skin
Type 4 presented with a 7‐year history of multiple
asymptomatic facial erythematous plaques,
which had been treated with miconazole nitrate
with hydrocortisone cream with no benefit. On
examination, she had multiple small discoid
erythematous plaques on her face (Figure 1b).
Differential diagnoses included DLE and psoria-
sis. Histological examination from one of the pla-
ques showed hyperkeratosis, acanthosis and a
dermal lymphocytic infiltrate (Figure 2b). Staining
for PAS was negative. She was treated for a
presumed clinical diagnosis of DLE, however,
failed to respond to topical steroids (mometasone
furoate 0.1% ointment and clobetasol propionate
0.05% ointment), tacrolimus 0.1% ointment and a
6‐month course of hydroxychloroquine 200 mg
twice daily. A repeat biopsy showed some psor-
iasiform changes, and therefore, she received a
course of NBUVB followed by calcipotriene oint-
ment which was ineffective.
Case 3 A 44‐year‐old female with Fitzpatrick
Skin Type 3 presented with asymptomatic facial
plaques which had gradually increased in
number and had been unresponsive to mildly
potent topical corticosteroids. She had a history
of depression treated with fluoxetine. Exami-
nation revealed 4 mildly scaly erythematous
discoid plaques on the face (Figure 1c). Skin
scraping was negative for mycology. Given the
clinical suspicion of DLE, a skin biopsy was
performed which showed hyperkeratosis, focal
parakeratosis, acanthosis, follicular plugging
and a dermal lymphocytic infiltrate (Figure 2c).
Treatment for presumed DLE with mometasone
furoate 0.1% ointment, clobetasol propionate
0.05% ointment and hydroxychloroquine
200 mg twice a day for 6 months was unsuc-
cessful. She was diagnosed with FDD and,
recognising the resistance of this condition to
treatment, she was not offered any further
therapeutic options.
3 | DISCUSSION
FDD was first reported in 2010. It is an under recog-
nised condition characterised by persistent orange‐pink
annular plaques, with variable surface scale, that
localise to the face and neck.1
Multiple therapies have been trialled without suc-
cess in the reports published to date.1–4 Topical
F I GURE 1 (a) Case 1 (b) Case 2 (c) Case 3. All three cases
showed well‐defined facial erythematous plaques
What is already known about this topic?
� Facial Discoid Dermatoses presents as pap-
ulosquamous lesions that localise to the face;
it is resistant to all therapies.
What does this study add?
� Increases the awareness of this condition so
that earlier diagnosis can be made.
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treatments include potent and very potent topical cor-
ticosteroids, vitamin D analogues, betamethasone/cal-
cipotriene ointment, antifungals, calcineurin inhibitors,
tazarotene cream, tretinoin 0.05% cream and imiqui-
mod cream. Oral treatments include doxycycline, itra-
conazole, acitretin, hydroxychloroquine, prednisolone
and methotrexate. Other treatments include intrale-
sional steroids, NBUVB and Pulsed dye laser.
Histologically, FDD demonstrates hyperkeratosis,
parakeratosis, acanthosis and follicular plugging. A
lymphocytic infiltrate in the superficial dermis is also
commonly seen.1–4 In the largest case series of eight
patients, additional histological features of subcorneal
acantholysis and checkerboard alternating orthoker-
atosis and parakeratosis were seen.2 The authors,
therefore, postulate that FDD may be a new variant of
pityriasis rubra pilaris. One of these cases went on to
develop Type 2 pityriasis rubra pilaris.2 However, as in
our case series, none of the other reported cases
developed extra‐facial disease. In all reported cases to
date, the condition has persisted without progression





The data that support the findings of this study are
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F I GURE 2 Haematoxylin and eosin staining
(a) Case 1, hyperkeratosis, parakeratosis,
acanthosis, follicular plugging and a
lymphocytic infiltration in the superficial dermis,
(b) Case 2, hyperkeratosis, acanthosis and a
dermal lymphocytic infiltrate (c) Case 3,
hyperkeratosis, focal parakeratosis,
acanthosis, follicular plugging and a dermal
lymphocytic infiltrate
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